Johnson & Weaver, LLP Initiates Investigations of Cognizant Technology Solutions Corporation, BofI Holding, Inc., Seres Therapeutics, Inc., SeaWorld Entertainment, Inc., and ProNAi Therapeutics, Inc.; Encourages Long-Term Investors to Contact the Firm Regarding Their Legal Rights

SAN DIEGO, Oct. 3, 2016 /PRNewswire/ -- Shareholder Rights Law Firm Johnson & Weaver, LLP, is investigating potential claims against Cognizant Technology Solutions Corporation, BofI Holding, Inc, Seres Therapeutics, Inc., SeaWorld Entertainment, Inc., and ProNAi Therapeutics, Inc., as detailed below.

Cognizant Technology Solutions Corporation

Johnson & Weaver, LLP, is investigating potential violations of the federal securities laws by Cognizant Technology Solutions Corporation (NASDAQ:CTSH) and certain of its officers. On September 30, 2016, Cognizant made known that it was conducting an internal investigation into whether certain payments in India violated the U.S. Foreign Corrupt Practices Act. Cognizant also announced that its president had resigned. On this news, shares of Cognizant closed down sharply on September 30, 2016.

If you have information that could assist in this investigation, including past employees and others, or if you are a Cognizant shareholder and are interested in learning more about the investigation or your legal rights and remedies, please contact Jim Baker ([email protected]) by email or phone at 619-814-4471. If emailing, please include a phone number where you can be reached.

BofI Holding, Inc.

Johnson & Weaver, LLP is investigating potential violations of federal and state  laws by BofI Holding, Inc. (NASDAQ: BOFI) and certain of its officers. A class action lawsuit against the Company has been filed on behalf of shareholders who purchased BofI stock between September 4, 2013 through October 13, 2015, (the "Class Period").

According to the complaint, Defendants made false and misleading statements and failed to disclose that: (1) BofI's internal controls were frequently disregarded; (2) BofI's borrowers included foreign nationals who should have been off-limits under federal anti-money-laundering laws; (3) many BofI accounts lacked required tax identification numbers; (4) BofI fired an internal auditor who raised these issues to management and to federal regulators; and (5) as a result of the above, BofI's statements regarding its internal controls and other financial statements were materially false and misleading at all relevant times.

If you have held BofI shares continuously prior to September 4, 2013, you may have standing to hold BofI harmless from the damage the officers and directors caused by making them personally responsible. You may also be able to assist in reforming the Company's corporate governance to prevent future wrongdoing.

If you are a BofI shareholder and are interested in learning more about the investigation or your legal rights and remedies, please contact lead analyst Jim Baker ([email protected]) at 619-814-4471. If you email, please include your phone number.

Seres Therapeutics, Inc.

Johnson & Weaver, LLP is investigating potential violations of the federal securities laws by Seres Therapeutics, Inc. (NASDAQ:MCRB) and certain of its officers. On July 29, 2016 Seres announced that its 8-week results from the ongoing SER-109 Phase 2 ECOSPOR™ clinical study for the prevention of multiply recurrent Clostridium difficile infection ("CDI") did not meet the primary endpoint of reducing the relative risk of CDI recurrence. On this news, the price of Seres' stock plummeted 69%.  Two days before the announcement, on July 27, 2016, Seres' President, Chief Executive Officer, and Chairman of the Board (Roger Pomerantz) sold 20,000 shares at much higher prices.  Another senior executive, on that same day, sold 38,064 shares at $35.1285 per share for gross proceeds of $1,337,510.

If you are a long-term, continuous holder of Seres stock, you may have standing to hold Seres harmless from the damage the officers and directors caused by making them personally responsible. You may also be able to assist in reforming the Company's corporate governance to prevent future wrongdoing.

If you are a Seres shareholder and are interested in learning more about the investigation or your legal rights and remedies, please contact lead analyst Jim Baker ([email protected]) at 619-814-4471. If you email, please include your phone number.

SeaWorld Entertainment, Inc.

Johnson & Weaver, LLP is investigating potential violations of federal and state laws by SeaWorld Entertainment, Inc. (NYSE: SEAS) and certain of its officers. A class action lawsuit against the Company was filed on behalf of shareholders who purchased SeaWorld between August 29, 2013 and August 12, 2014, (the "Class Period").

The complaint filed in the class action lawsuit alleges that SeaWorld and certain of its officers and directors made false and misleading statements and failed to disclose information regarding the critically acclaimed 2013 documentary Blackfish – a film which the complaint alleges had a profound impact on attendance at SeaWorld-branded parks throughout the Class Period, as it damaged the public's perception of SeaWorld and degraded the Company's core brand and business. On September 29, 2016, the Court issued a tentative ruling denying defendants' motion to dismiss the federal class action.

If you have held SeaWorld shares continuously prior to December 2013, you may have standing to hold SeaWorld harmless from the damage the officers and directors caused by making them personally responsible. You may also be able to assist in reforming the Company's corporate governance to prevent future wrongdoing.

If you are a SeaWorld shareholder and are interested in learning more about the investigation or your legal rights and remedies, please contact lead analyst Jim Baker ([email protected]) at 619-814-4471. If you email, please include your phone number.

ProNAi Therapeutics, Inc.

Johnson & Weaver, LLP is investigating potential violations of the federal securities laws by ProNAi Therapeutics, Inc. (NASDAQ: DNAI) and certain of its officers. On July 16, 2015, ProNAi's stock traded as high as $33.75, the same day the Company sold 8.1 million shares of stock in its initial public stock offering (the "IPO"), raising $137.7 million in new capital. However, since the IPO, ProNAi's stock has tumbled, closing at $1.82 on September 30, 2016.

On June 6, 2016, ProNAi released its interim results from the Wolverine Phase 2 trial of PNT2258 for the treatment of relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL). Nick Glover, President and CEO said, "Although [PNT2258] observed modest efficacy …in [the] interim analysis of Wolverine," the Company has "decided to suspend the development of PNT2258" because the results were not "robust enough to justify continued development of the drug in DLBCL." Specifically, Johnson & Weaver's investigation seeks to determine whether certain statements regarding the Company's business metrics and financial prospects were not as strong as represented in the Registration Statement. 

If you are a ProNAi shareholder and are interested in learning more about the investigation or your legal rights and remedies, please contact lead analyst Jim Baker ([email protected]) at 619-814-4471. If you email, please include your phone number.

About Johnson & Weaver, LLP:

Johnson & Weaver, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonandweaver.com. Attorney advertising. Past results do not guarantee future outcomes.

Contact:
Johnson & Weaver, LLP
Jim Baker, 619-814-4471
[email protected]

Logo - http://photos.prnewswire.com/prnh/20160211/332409LOGO

SOURCE Johnson & Weaver, LLP

Related Links

http://johnsonandweaver.com